Similar articles for PMID: 21502062

Year	Number of Results
1900	1
1916	2
1946	1
1947	2
1949	1
1950	1
1975	1
1976	1
1977	1
1983	2
1984	2
1991	2
1994	2
1995	2
1996	1
1999	2
2001	2
2002	1
2003	1
2004	2
2005	4
2006	5
2007	4
2008	1
2009	3
2010	9
2011	9
2012	16
2013	13
2014	8
2015	8
2016	4
2017	10
2018	5
2019	4
2020	1
2021	6

1

Importance of early characterization of physicochemical properties in developing high-dose intravenous infusion regimens for poorly water-soluble compounds.

Jain A, Zheng W, Garad S, Weaver M, Panicucci R. Jain A, et al. PDA J Pharm Sci Technol. 2010 Nov-Dec;64(6):517-26. PDA J Pharm Sci Technol. 2010. PMID: 21502062

2

Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.

Li S, Pollock-Dove C, Dong LC, Chen J, Creasey AA, Dai WG. Li S, et al. Mol Pharm. 2012 May 7;9(5):1100-8. doi: 10.1021/mp200352q. Epub 2012 Apr 13. Mol Pharm. 2012. PMID: 22376012

3

In Vitro Screening Methods To Assess the Potential of In Vivo Precipitation of Injectable Formulations upon Intravenous Administration.

Sheth AR. Sheth AR. PDA J Pharm Sci Technol. 2011 Jan-Feb;65(1):71-80. PDA J Pharm Sci Technol. 2011. PMID: 21414942

4

Recent advances in intravenous delivery of poorly water-soluble compounds.

Shi Y, Porter W, Merdan T, Li LC. Shi Y, et al. Expert Opin Drug Deliv. 2009 Dec;6(12):1261-82. doi: 10.1517/17425240903307423. Expert Opin Drug Deliv. 2009. PMID: 19941409 Review.

5

Methods to evaluate and improve the injection site tolerability of intravenous formulations prior to first-in-human testing.

Eichenbaum G, Zhou J, De Smedt A, De Jonghe S, Looszova A, Arien T, Van Goethem F, Vervoort I, Shukla U, Lammens L. Eichenbaum G, et al. J Pharmacol Toxicol Methods. 2013 Nov-Dec;68(3):394-406. doi: 10.1016/j.vascn.2013.08.002. Epub 2013 Aug 8. J Pharmacol Toxicol Methods. 2013. PMID: 23933112

6

Risk assessment and physicochemical characterization of a metastable dihydrate API phase for intravenous formulation development.

Mortko CJ, Sheth AR, Variankaval N, Li L, Farrer BT. Mortko CJ, et al. J Pharm Sci. 2010 Dec;99(12):4973-81. doi: 10.1002/jps.22225. J Pharm Sci. 2010. PMID: 20821397

7

Development and validation of in silico models for estimating drug preformulation risk in PEG400/water and Tween80/water systems.

Crivori P, Morelli A, Pezzetta D, Rocchetti M, Poggesi I. Crivori P, et al. Eur J Pharm Sci. 2007 Nov;32(3):169-81. doi: 10.1016/j.ejps.2007.06.008. Epub 2007 Aug 21. Eur J Pharm Sci. 2007. PMID: 17714921

8

Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters.

Bittner B, Mountfield RJ. Bittner B, et al. Curr Opin Drug Discov Devel. 2002 Jan;5(1):59-71. Curr Opin Drug Discov Devel. 2002. PMID: 11865674 Review.

9

A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat.

Banfor PN, Gintant GA, Lipari JM, Zocharski PD. Banfor PN, et al. J Pharmacol Toxicol Methods. 2016 Nov-Dec;82:62-67. doi: 10.1016/j.vascn.2016.07.002. Epub 2016 Jul 16. J Pharmacol Toxicol Methods. 2016. PMID: 27432021

10

Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.

Ban K, Sonohara R, Yoshida M, Sako K, Uchida S, Namiki N. Ban K, et al. PDA J Pharm Sci Technol. 2013 Jul-Aug;67(4):336-53. doi: 10.5731/pdajpst.2013.00926. PDA J Pharm Sci Technol. 2013. PMID: 23872444

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed